Valuation: Pluristem Therapeutics Inc.

Market Cap 12.78M 11.35M 10.63M 9.63M 18.15M 1.23B 18.3M 128M 49.61M 628M 47.96M 46.93M 2.02B P/E 2025
-1.39x
P/E 2026 -0.85x
Enterprise Value 39.89M 35.42M 33.18M 30.05M 56.67M 3.84B 57.13M 398M 155M 1.96B 150M 146M 6.31B EV / Sales 2025
39,078,124x
EV / Sales 2026 48,878,101x
Free-Float
57.48%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 54 2017-03-28
Director of Finance/CFO 42 2022-11-30
Chief Operating Officer - 2024-12-31
Director TitleAgeSince
Director/Board Member 54 2015-01-31
Director/Board Member 56 2021-01-05
Director/Board Member 64 2021-05-31
Change 5-day change 1-year change 3-year change Capi.($)
+11.70%-24.18% - - 12.78M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-0.93%+327.90%+691.25% 44.51B
-2.30%-4.06%+25.82%+31.42% 43.8B
+0.31%-1.15%+5.50%+112.56% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-3.38%-9.25%-12.85% 24.53B
Average +1.55%-0.20%+52.55%+125.61% 43.73B
Weighted average by Cap. +0.77%-0.50%+56.58%+134.21%

Financials

2025 2026
Net sales 1.34 1.19 1.11 1.01 1.9 128.74 1.91 13.34 5.19 65.66 5.01 4.91 211.3 1.02 0.9 0.85 0.77 1.44 97.9 1.46 10.15 3.94 49.94 3.81 3.73 160.69
Net income -22.58M -20.06M -18.79M -17.01M -32.09M -2.18B -32.34M -226M -87.69M -1.11B -84.76M -82.94M -3.57B -23.82M -21.16M -19.82M -17.95M -33.84M -2.3B -34.12M -238M -92.49M -1.17B -89.41M -87.49M -3.77B
Net Debt 13.44M 11.93M 11.18M 10.12M 19.09M 1.29B 19.24M 134M 52.17M 660M 50.43M 49.35M 2.13B 27.11M 24.08M 22.55M 20.42M 38.52M 2.61B 38.83M 271M 105M 1.33B 102M 99.57M 4.29B
Logo Pluristem Therapeutics Inc.
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.
Employees
-